Evidence map›Paper›PMID 42148540›Full record

ArticleJournal of medical virology2026

Vaccination Coverage Against Coronavirus Disease 2019 (COVID-19) in Brazil's Indigenous Population.

Nathália Mariana Santos Sansone, Patrícia Teixeira Costa, Lucas Silva Mello, Luiz Felipe Azevedo Marques, Vinícius Santiago Dos Santos, Fernando Augusto Lima Marson

Abstract read
In one paragraph

Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nathália Mariana Santos SansoneLaboratory of Molecular Biology and Genetics, Postgraduate Program in Health Sciences, Postgraduate Program in Health Data Science, São Francisco University (USF; acronym for Universidade São Francisco), Bragança Paulista, São Paulo, Brazil.ORCID https://orcid.org/0000-0003-4398-9245
Patrícia Teixeira CostaLaboratory of Molecular Biology and Genetics, Postgraduate Program in Health Sciences, Postgraduate Program in Health Data Science, São Francisco University (USF; acronym for Universidade São Francisco), Bragança Paulista, São Paulo, Brazil.ORCID https://orcid.org/0009-0002-8179-5644
Lucas Silva MelloLaboratory of Molecular Biology and Genetics, Postgraduate Program in Health Sciences, Postgraduate Program in Health Data Science, São Francisco University (USF; acronym for Universidade São Francisco), Bragança Paulista, São Paulo, Brazil.ORCID https://orcid.org/0009-0006-9920-5058
Luiz Felipe Azevedo MarquesLaboratory of Molecular Biology and Genetics, Postgraduate Program in Health Sciences, Postgraduate Program in Health Data Science, São Francisco University (USF; acronym for Universidade São Francisco), Bragança Paulista, São Paulo, Brazil.ORCID https://orcid.org/0009-0008-5494-2171
Vinícius Santiago Dos SantosLaboratory of Molecular Biology and Genetics, Postgraduate Program in Health Sciences, Postgraduate Program in Health Data Science, São Francisco University (USF; acronym for Universidade São Francisco), Bragança Paulista, São Paulo, Brazil.ORCID https://orcid.org/0009-0000-9549-6069
Fernando Augusto Lima MarsonLaboratory of Molecular Biology and Genetics, Postgraduate Program in Health Sciences, Postgraduate Program in Health Data Science, São Francisco University (USF; acronym for Universidade São Francisco), Bragança Paulista, São Paulo, Brazil.ORCID https://orcid.org/0000-0003-4955-4234

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 305906/2024-0Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 8887.892875/2023-00Fundação de Amparo à Pesquisa do Estado de São Paulo 2024/20055-9Fundação de Amparo à Pesquisa do Estado de São Paulo 2024/20061-9
6 · The paper itself

Abstract

Indigenous populations in Brazil were prioritized for coronavirus disease 2019 (COVID-19) vaccination due to their increased vulnerability. The aim of the study was to describe COVID-19 vaccination coverage among Indigenous population across Brazilian regions and Special Indigenous Health Districts (DSEIs; acronym for Distritos Sanitários Especiais Indígenas). A retrospective study was conducted using data from January 17, 2021, to June 27, 2024, obtained from the open-access COVID-19 vaccination database made available by the Brazilian Ministry of Health, covering the 4-year period of the pandemic. The dataset included information on the Indigenous population (number of inhabitants), as well as the number and type of vaccine doses administered (first dose, second dose, single dose, and booster dose). Second dose refers to vaccines requiring a two-dose primary schedule, whereas single-dose refers to vaccines administered as a single primary dose; booster dose refers to any additional dose given after completion of the primary vaccination schedule and, according to the database, was restricted to individuals aged ≥ 18 years. Vaccination coverage was calculated by dividing the number of doses administered by the total Indigenous population, based on estimated from the 2022 Brazilian Institute of Geography and Statistics (IBGE; acronym for Instituto Brasileiro de Geografia e Estatística) Census, and multiplying by 100. The data was analyzed and presented according to Brazil's federative units (states and the Federal District) and DSEIs. A total of 1 490 036 COVID-19 vaccine doses were administered to the Indigenous population. Of these, 631 990 (42%) corresponded to first doses, 551 602 (27%) to second or single doses, and 306 444 (21%) to booster doses. These doses corresponded to vaccination coverage of 89%, 78%, and 43% of the Indigenous population (N = 707 739), respectively. Across the 27 federative units, the lowest coverage for the first dose was observed in Tocantins (83%), Roraima (74%), and Pará (73%), while for second or single doses the lowest rates were found in Amapá (63%), Roraima (60%), and Pará (58%). Among the 34 DSEIs, 13 (38.2%) did not reach 90% coverage for the first dose, and 21 (61.8%) did not reach this threshold for the second or single doses. The lowest coverage levels were identified in Araguaia (65% and 44%), Rio Tapajós (59% and 40%), and Kaiapó do Pará (56% and 34%) for first and second or single doses, respectively. Vaccination coverage against COVID-19 among Brazil's Indigenous population has not fully reached the 90% target recommended by the Brazilian government in alignment with the World Health Organization after 4 years of the pandemic. This gap may be explained by multiple factors, including cultural barriers, remote geographic conditions, and logistical challenges related to vaccine distribution.

Indexed as

COVID-19COVID-19 VaccinesIndigenous PeoplesVaccination CoverageAdolescentAdultAgedBrazilFemaleHumansMaleMiddle AgedRetrospective StudiesSARS-CoV-2VaccinationYoung AdultCOVID-19 VaccinesepidemiologyIndigenouspandemicpublic healthSARS‐CoV‐2vaccinesvulnerable population

Identifiers

PMID42148540
PMCPMC13182200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.